Infliximab therapy
Infliximab was administered intravenously 3-5 mg/kg bodyweight every fourth to eight weeks after an initial induction phase. During the study period a consensus document on infliximab therapy was published20, recommending a dose of 5 mg/kg bodyweight, and infusion every fourth week after the initial induction phase. Patients included thereafter, were therefore treated according to these recommendations, i.e. given a higher dose and more frequently than patients included in the beginning of the study. For individual total doses, see Supplement 2. During the study period, biosimilars appeared on the market. Patients 1-4 and 12-13 received Remicade®, Merck Sharpe &Dome AB (Sweden) while the rest received the biosimilar Inflectra®, Pfizer AB (Sweden).